- Home
- SUZ vs BMRN Comparison
SUZ vs BMRN Comparison
Compare SUZ & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SUZ | BMRN |
|---|---|---|
| Founded | 1924 | 1996 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Paper | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8B | 11.4B |
| IPO Year | 2002 | 1999 |
Fundamental Metrics
Financial Performance| Metric | SUZ | BMRN |
|---|---|---|
| Price | $9.06 | $65.31 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 18 |
| Target Price | N/A | ★ $88.22 |
| AVG Volume (30 Days) | ★ 3.4M | 2.2M |
| Earning Date | 05-11-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.15% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.77 |
| Revenue | N/A | ★ $1,313,646,000.00 |
| Revenue This Year | $13.28 | $15.02 |
| Revenue Next Year | $13.57 | $12.23 |
| P/E Ratio | ★ $5.58 | $86.62 |
| Revenue Growth | N/A | ★ 17.62 |
| 52 Week Low | $7.56 | $49.26 |
| 52 Week High | $11.54 | $70.98 |
Technical Indicators
Market Signals| Indicator | SUZ | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 69.62 | 53.42 |
| Support Level | $8.78 | $58.03 |
| Resistance Level | $9.68 | $70.98 |
| Average True Range (ATR) | 0.24 | 2.24 |
| MACD | 0.09 | -0.18 |
| Stochastic Oscillator | 92.55 | 52.44 |
Price Performance
Historical ComparisonAbout SUZ Suzano S.A.
Suzano SA produces and sells pulp and a variety of paper products. The company organizes itself into two segments based on product type: Pulp and Paper. The Pulp segment generates the majority of revenue. The firm's product portfolio includes printing and writing paper, paperboard, diapers, and sanitary napkins. The company owns forest land and plants in Brazil, where it harvests timber and turns the timber into pulp and paper in its plants.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.